Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease.
Interleukin-1 receptor antagonist (IL-1Ra) is a good indicator of disease activity in patients with systemic lupus erythematosus (SLE). Glucocorticosteroids are the most frequently used drugs in SLE. Our goal was to compare IL-1Ra activity in SLE patients with and without renal involvement and to determine the effect of different dosage of glucocorticosteroids used in 17 patients with active SLE without nephritis, 7 patients with inactive lupus nephritis (LN), and 8 patients with active LN, along with 10 healthy controls. IL-1Ra levels were measured in the serum of SLE patients by Human Luminex [100] analyzer. Both in patients with active SLE without nephritis and in patients with LN, serum levels of IL-1Ra (p<0.001) were significantly higher compared with those in the controls. IL-1Ra was significantly higher in patients with active LN than in patients with inactive LN (p = 0.028). The use of methylprednisolone was significantly higher in the active LN group compared with the inactive LN group (p = 0.013). SLE patients with higher IL-1Ra are at lower risk for developing nephritis. The higher doses of glucocorticosteroids needed in active LN could be due to steroid resistance and IL-1Ra polymorphism. Measurement of IL-1Ra levels in SLE patients could help to predict future renal involvement.
Brugos
Boglarka
B
3rd Department of Internal Medicine, Division of Clinical Immunology, Medical and Health Science Center of University of Debrecen, Debrecen, Hungary.
Kiss
Emese
E
Dul
Csaba
C
Gubisch
Wolfgang
W
Szegedi
Gyula
G
Sipka
Sandor
S
Zeher
Margit
M
D000328:Adult; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005919:Glomerular Filtration Rate / Q000502:physiology; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D008181:Lupus Nephritis / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008657:Metabolic Clearance Rate / Q000502:physiology; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D011507:Proteinuria / Q000652:urine; D012720:Severity of Illness Index; D055815:Young Adult; D053482:beta 2-Glycoprotein I / Q000097:blood
D015415:Biomarkers; D053590:Interleukin 1 Receptor Antagonist Protein; D053482:beta 2-Glycoprotein I; D016572:Cyclosporine; D003520:Cyclophosphamide; D002097:C-Reactive Protein; D003404:Creatinine; D008775:Methylprednisolone